When BMI and comorbidity thresholds are met for anti obesity pharmacotherapy, GLP-1 agonists are recommended as first line or preferred pharmacologic options because of superior weight loss efficacy and cardiometabolic benefit
A separate trial (ATTAIN-MAINTAIN) tested whether people who had already lost weight on injectable Wegovy or Mounjaro could maintain that weight loss by switching to oral orforglipron
The vulnerability of this system to free radicals demand for advanced strategies to combat them
Provider Demand: Endocrinologists, dietitians and primary care physicians may experience appointment volume increases as patients seek guidance and prescriptions for GLP-1 therapies
When you come by our location, our team can help you set up the schedule that suits you best
Quick Comparison : Key Takeaway : GLP-1 therapies may offer better weight loss and metabolic improvements, but side effects, cost, and access limit adherence